Table 2.
Distribution of Breast Cancer Tumor Subtypes in the Ella Study by Country
| Tumor subtype | No. of patients (%)
|
||
|---|---|---|---|
| Total n = 1041 | US n = 559 | Mexico n = 482 | |
| ER− | 347 (33.3) | 152 (27.2) | 195 (40.5) |
| ER+ | 694 (66.7) | 407 (72.8) | 287 (59.5) |
| PR− | 408 (39.8) | 209 (37.8) | 199 (42.2) |
| PR+ | 617 (60.2) | 344 (62.2) | 273 (57.8) |
| PR unknown | 16 | 6 | 10 |
| luminal A | 571 (59.8) | 330 (61.2) | 241 (57.9) |
| HER2− | 735 (72.6) | 410 (74.6) | 325 (70.2) |
| HER2+ | 225 (22.2) | 131 (23.8) | 94 (20.3) |
| HER2 equivocal | 53 (5.23) | 9 (1.64) | 44 (9.50) |
| HER2+a | 225 (23.6) | 131 (24.3) | 94 (22.6) |
| HER2 unknown | 28 | 9 | 19 |
| TNBC | 159 (16.7) | 78 (14.5) | 81 (19.5) |
| Subtype unknown | 86 | 20 | 66 |
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; luminal A, hormone receptor; PR, progesterone receptor; TNBC, triple negative breast cancer; US, United States.
a
Excludes women with equivocal immunohistochemistry scores.